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Introduction
Invasive lobular carcinoma (ILC) is the second most prev-
alent type of breast cancer based on histological criteria. 
Approximately 10%–15% of primary breast cancers fall into 
this category.1,2 These carcinomas are in general more estro-
gen receptor (ER)-positive, more human epidermal growth 
factor receptor 2 (HER2)-negative, and of lower histological 
grade compared to the more common invasive ductal carci-
nomas (IDCs).3,4 Pathological assessment of ILCs identified 
four different subtypes, illustrating heterogeneity in this 
group of tumors. There is a tendency to classify ILC as a type 
with low risk of relapse; however, available reports on survival 
data show heterogeneous outcome statistics.2 As a result, in 
current clinical practice, it is unclear which ILC patients are 
at increased risk of tumor recurrence and whether there are 
patients who would benefit from specific treatment options. 
Treatment decisions for early-stage ILCs may benefit from 
clinical adoption of the MammaPrint® test, in addition to 
evaluation of clinicopathological parameters, as is already 
common in clinical practice for IDCs, especially because 
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abstract
background: MammaPrint® is a microarray-based gene expression test cleared by the US Food and Drug Administration to assess recurrence risk 
in early-stage breast cancer, aimed to guide physicians in making neoadjuvant and adjuvant treatment decisions. The increase in the incidence of invasive 
lobular carcinomas (ILCs) over the past decades and the modest representation of ILC in the MammaPrint development data set calls for a stratified sur-
vival analysis dedicated to this specific subgroup.
study aIm: The current study aimed to validate the prognostic value of the MammaPrint test for breast cancer patients with early-stage ILCs.
materIals and methods: Univariate and multivariate survival associations for overall survival (OS), distant metastasis-free interval (DMFI), 
and distant metastasis-free survival (DMFS) were studied in a study population of 217 early-stage ILC breast cancer patients from five different 
clinical studies.
results and dIscussIon: A significant association between MammaPrint High Risk and poor clinical outcome was shown for OS, DMFI, and 
DMFS. A subanalysis was performed on the lymph node-negative study population. In the lymph node-negative study population, we report an up to 
11 times higher change in the diagnosis of an event in the MammaPrint High Risk group. For DMFI, the reported hazard ratio is 11.1 (95% confidence 
interval = 2.3–53.0).
conclusIon: Study results validate MammaPrint as an independent factor for breast cancer patients with early-stage invasive lobular breast cancer. 
Hazard ratios up to 11 in multivariate analyses emphasize the independent value of MammaPrint, specifically in lymph node-negative ILC breast cancers.
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systemic treatment options for both types of tumors are 
currently almost identical.4
The MammaPrint assay is a microarray-based test 
cleared by the US Food and Drug Administration, which 
uses the expression levels of the 70 MammaPrint genes to 
assess risk of recurrence in early-stage breast cancer.5–7 The 
test aims to guide physicians in making neoadjuvant and adju-
vant treatment decisions. This assay was developed and vali-
dated in cohorts of breast cancer patients, which consisted of 
approximately 85% of the more prevalent type of IDC. This 
dominance of IDC in the MammaPrint training and validation 
sets could potentially introduce a bias in the prognostic perfor-
mance of the MammaPrint assay in favor of IDC, with the 
gene signature being more correctly prognostic in IDC than in 
ILC. However, a pathway analysis of the 70 signature genes of 
the MammaPrint assay demonstrated that the test measures a 
number of universal aspects of (breast) cancer bio logy, includ-
ing proliferation, angiogenesis, invasion, and ER signaling, and 
it is likely that these processes are very similar in breast cancers 
of different origins.8 A recurrent clinical question about Mam-
maPrint involves its prognostic value for specifically the ILC 
group of breast cancers. Some physicians feel that the smaller 
representation of invasive lobular cancers in the development 
data set calls for a survival analysis dedicated to this specific 
subgroup to determine the prognostic value of MammaPrint.
With the increase in the incidence of ILCs over the past 
decades,9,10 there is a clear clinical need to better evaluate 
the prognostic value of the MammaPrint test for specifically 
invasive lobular breast carcinomas. Hence, we have sought to 
validate the prognostic capacity of MammaPrint in primary 
invasive lobular breast cancers. The results of this evaluation 
are presented here.
materials and methods
Patient samples. MammaPrint results,6 clinicopatho-
logical data, and survival data were collected for all early breast 
cancers of the invasive lobular type from Agendia’s clinical 
series database. The study population consisted of 217 unique 
cases that were derived from five clinical series, including 
the RAtional THerapy for breast cancER (RATHER) ILC 
series,11 and the microarRAy-prognoSTics-in-breast-cancER 
(RASTER) series12 (refer Supplementary File 1 for detailed 
information).11–14 Clinicopathological data included age at 
surgery, differentiation grade, lymph node (LN) involvement, 
surgery type, and administration of adjuvant chemotherapy 
and hormone therapy. Additionally, information on ER status 
and HER2 status, as assessed by the TargetPrint assay,15 was 
available for analyses. TargetPrint readout was as described 
previously by Roepman et al.15 The mean follow-up time for this 
study cohort was 85 months (range: four months–22 years).
Research was performed according to the principles of the 
Declaration of Helsinki. All patient samples and data were anon-
ymously coded in accordance with national ethical guidelines 
(“Code for Proper Secondary Use of Human Tissues”, Dutch 
Federation of Medical Scientific Societies), and the study 
samples had institutional review board approvals for the ano-
nymized use of archival tissues.11–14 This study was performed 
based on the guidance of the REporting recommendations for 
tumor MARKer prognostic studies (REMARK)  (National 
Cancer Institute–European Organisation for Research and 
Treatment of Cancer [NCI-EORTC]).16
data analysis. Statistical analyses, survival analyses, and 
visualization of data were performed using the statistical pack-
age SPSS 22.0 for Windows (SPSS Inc, Chicago, IL, USA).
The relationship between MammaPrint results (Mamma-
Print index values dichotomized to Low Risk and High 
Risk) and known clinicopathological parameters was investi-
gated using the Pearson chi-squared test or Fisher’s exact test.
MammaPrint results were used in survival analyses. 
The Cox proportional-hazards model was used to analyze 
the association between MammaPrint results for survival 
at 10 years after surgery. Overall survival (OS) was defined 
as the time from surgery until death by any cause.17 Dis-
tant metastasis-free interval (DMFI) was defined as the 
time from surgery until the diagnosis of a distant recur-
rence. Distant metastasis-free survival (DMFS) was defined 
as the time from surgery until the diagnosis of a distant 
metastasis or death by any cause.17 Differences in survival 
between patient groups are presented as hazard ratios (HRs). 
The MammaPrint Low Risk group was used as the refer-
ence group for all survival analyses. Kaplan–Meier curves 
were used to visualize the univariate survival associations. 
Multivariate survival analyses were performed to account 
for the effects of other variables or confounders on survival 
and to account for potential differences in distribution of 
clinicopathological factors between Mamma Print Low 
Risk and High Risk groups. Multivariate models included 
the following predetermined clinically important covari-
ates: age at surgery, LN involvement, differentiation grade, 
adjuvant chemotherapy, ER status, and HER2 status, irre-
spective of statistical significance. Age at surgery and dif-
ferentiation grade were entered as continuous variables into 
the multivariate models. All tests were two-tailed types, and 
P-values , 0.05 were considered statistically significant.
results
Patient characteristics. Clinicopathological and sur-
vival data were available for n = 217 invasive lobular cases. 
These cases originate from multiple clinical study series, 
as described in the “Materials and Methods” section. The 
association of MammaPrint verdict results (Low Risk and 
High Risk for MammaPrint) with clinicopathological param-
eters is described in Table 1. Analyses were performed for the 
entire study cohort (n = 217), as well as for the group of LN-
negative cases (n = 144). MammaPrint verdict results of the 
entire study cohort correlated with the established prognostic 
parameter of LN involvement, with the MammaPrint Low 
Risk group containing slightly more LN-negative tumors. 
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Most patients had ER-positive and HER2-negative disease. 
The mean patient age at surgery was 58 years (range: 29–93 
years). As expected, a higher percentage of breast-conserving 
therapy was the choice of surgery for MammaPrint Low Risk 
patients, and less patients in the MammaPrint Low Risk group 
received adjuvant chemotherapy. Interestingly, we observed 
more patients older than 55 years in the MammaPrint High 
Risk group compared to those in the Low Risk group.
Prognostic value of mammaPrint in the Ilc subgroup. 
Results of univariate survival analyses are shown in Table 2, 
and visualized in Kaplan–Meier curves (Fig. 1). A significant 
association between MammaPrint High Risk and poor clini-
cal outcome was shown in univariate analyses for OS, DMFI, 
and DMFS. Based on the univariate analyses, patients with 
tumors classified as High Risk showed a 3.6 times higher 
chance to develop a distant metastasis within 10 years after sur-
gery (DMFI HR: 3.6; 95% confidence interval [CI]: 1.6–7.8) 
or to die within 10 years after surgery (OS HR: 3.6; 95% CI: 
1.8–7.0), and a 3.3 times higher chance to present with either 
event (DMFS HR: 3.3; 95% CI: 1.8–6.1).
Results of multivariate survival analyses are shown in 
Table 3. In multivariate analyses, MammaPrint was validated 
as an independent factor for DMFI and DMFS. MammaPrint 
High Risk status was associated with worse clinical outcome 
in invasive lobular breast cancer. In these analyses, accounting 
for the effect of confounders or differences in distribution of 
clinicopathological factors between analyses groups, patients 
with a tumor classified as MammaPrint High Risk showed a 
2.4 times higher chance to develop a distant metastasis within 
10 years after surgery (DMFI HR: 2.4; 95% CI: 1.0–5.6). 
The chance to develop a distant metastasis or die within 
10 years after surgery was 2.1 times higher in the Mamma-
Print High Risk group (DMFS HR: 2.1; 95% CI: 1.0–4.1). 
Multivariate survival analyses were further performed by 
including only those clinicopathological parameters that 
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figure 1. Univariate survival curves for invasive lobular breast cancer stratified by MammaPrint. 
notes: Kaplan–Meier curves illustrating survival for invasive lobular breast cancer patients stratified by MammaPrint result. All cases of the study 
cohort (n = 217) were included. Curves were plotted for the end points overall survival (os) (a), distant metastasis-free interval (DmFi) (B), and distant 
metastasis-free survival (DmFs) (C) to assess the difference in univariate survival between mammaPrint Low risk (green line) and mammaPrint high 
risk (red line) tumors in the subgroup of invasive lobular breast cancers. the x-axis represents time in months from surgery until the diagnosis of an 
event. The y-axis represents cumulative survival (refer “Materials and Methods” section for survival definitions). Tables below the Kaplan–Meier curves 
give the numbers at risk at specific time points. 
abbreviations: hr, high risk for mammaPrint; Lr, Low risk for mammaPrint; mP, mammaPrint.
table 2. Univariate survival associations for invasive lobular breast cancer.
oVERaLL SuRVIVaL  
(at 10 YEaRS)
dIStant MEtaStaSIS fREE  
IntERVaL (at 10 YEaRS)
dIStant MEtaStaSIS fREE  
SuRVIVaL (at 10 YEaRS)
hR 95% CI P-VaLuE hR 95% CI P-VaLuE hR 95%CI P-VaLuE
all cases
mammaPrint hr/Lr 3.577 1.842–6.948 ,0.001 3.556 1.621–7.799 0.002 3.308 1.789–6.116 ,0.001
Ln-negative cases
mammaPrint hr/Lr 7.465 2.582–21.583 ,0.001 10.535 2.496–44.465 0.001 7.806 2.892–21.068 ,0.001
notes: shown are data from univariate survival analyses of mammaPrint for the invasive lobular breast cancer study cohort at 10 years after surgery.  
hr .1 indicates that the hr group has a worse clinical outcome compared to the Lr group. the reference group for each covariate in the multivariate model is 
underlined in column 2. For significant associations, P-values are indicated in bold.
abbreviations: CI, confidence interval; HR, hazard ratio; HR, High Risk for MammaPrint; LR, Low Risk for MammaPrint.
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figure 2. Univariate survival curves for invasive lobular breast cancer without lymph node involvement stratified by MammaPrint. 
notes: kaplan–meier curves illustrating survival for invasive lobular breast cancer patients without Ln involvement (n = 144), stratified by MammaPrint 
result. Curves were plotted for the end points overall survival (os) (a), distant metastasis-free interval (DmFi) (B), and distant metastasis-free survival 
(DmFs) (C) to assess the difference in univariate survival between mammaPrint Low risk (green line) and mammaPrint high risk (red line) tumors in 
the subgroup of invasive lobular breast cancers. the x-axis represents time in months from surgery until the diagnosis of an event. the y-axis represents 
cumulative survival (refer “Materials and Methods” section for survival definitions). Tables below the Kaplan–Meier curves give the numbers at risk at 
specific time points. 
abbreviations: hr, high risk for mammaPrint; Lr, Low risk for mammaPrint; mP, mammaPrint.
table 3. multivariate survival associations for invasive lobular breast cancer.
oVERaLL SuRVIVaL  
(at 10 YEaRS)
dIStant MEtaStaSIS fREE  
IntERVaL (at 10 YEaRS)
dIStant MEtaStaSIS fREE  
SuRVIVaL (at 10 YEaRS)
hR 95% CI P-VaLuE hR 95% CI P-VaLuE hR 95%CI P-VaLuE
all cases
mammaPrint hr/Lr 2.015 0.944–4.299 0.070 2.362 1.004–5.556 0.049 2.078 1.045–4.135 0.037
agea continuous 1.693 1.228–2.336 0.001 1.209 0.817–1.789 0.341 1.444 1.069–1.949 0.016
Ln group pos/neg 2.150 1.024–4.514 0.043 2.999 1.180–7.620 0.021 2.335 1.168–4.665 0.016
Differentiation grade continuous 1 to 3 2.123 0.805–5.605 0.128 1.719 0.673–4.388 0.257 1.432 0.653–3.142 0.370
Chemotherapy yes/no 1.015 0.347–2.967 0.979 1.285 0.428–3.861 0.655 0.989 0.379–2.577 0.981
er statusb pos/neg 0.290 0.103–0.819 0.019 0.443 0.105–1.859 0.266 0.280 0.103–0.760 0.012
her2 statusb pos/neg 0.202 0.043–0.963 0.045 0.436 0.104–1.833 0.257 0.312 0.088–1.110 0.072
Ln-negative cases
mammaPrint hr/Lr 5.102 1.516–17.174 0.008 11.12 2.332–53.020 0.003 6.399 2.136–19.171 0.001
agea continuous 1.429 0.877–2.331 0.152 1.099 0.529–2.286 0.800 1.361 0.855–2.169 0.194
Differentiation grade continuous 1 to 3 1.312 0.250–6.889 0.748 0.892 0.121–6.556 0.911 1.023 0.245–4.273 0.975
Chemotherapy yes/no 0.606 0.062–5.884 0.666 0.720 0.065–7.991 0.789 0.418 0.047–3.714 0.434
er statusb pos/neg 0.220 0.049–0.985 0.048 0.522 0.050–5.405 0.585 0.272 0.068–1.088 0.066
her2 statusb pos/neg 0.576 0.062–5.329 0.627 0.662 0.051–8.515 0.752 1.002 0.179–5.615 0.998
notes: shown are data from multivariate survival analyses of mammaPrint for the invasive lobular breast cancer study cohort at 10 years after surgery. hr .1 
indicates that the hr group has a worse clinical outcome compared to the Lr group. the reference group for each covariate in the multivariate model is underlined 
in column 2. For significant associations, P-values are indicated in bold. the covariates “age at surgery” and “differentiation grade” were entered as continuous 
variables into the multivariate model. aFor age at surgery, the hr is given per unit increase, with one unit representing 10-year increase in age. ber status and 
her2 status were assessed by targetPrint.15
abbreviations: CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; HR, High Risk for MammaPrint; 
Ln, lymph node; Lr, Low risk for mammaPrint.
(Supplementary File 2). These analyses confirm MammaPrint 
as independent factor for OS, DMFI, and DMFS.
Prognostic value of mammaPrint in Ilc without ln 
involvement. In the patient group without LN involvement 
(n = 144), MammaPrint was validated for OS, DMFI, and 
DMFS in univariate (Table 2) and multivariate (Table 3) sur-
vival analyses. Additionally, Kaplan–Meier curves were plot-
ted to visualize the univariate survival associations (Fig. 2). 
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The lower number of cases in the LN-negative subgroup 
as compared to the whole study cohort inherently resulted 
in wider CIs. Based on univariate analyses, patients with 
tumors classified as High Risk showed a 7.5–10.5 times 
higher chance for an OS-related event (OS HR: 7.5; 95% CI: 
2.6–21.6), DMFI (DMFI HR: 10.5; 95% CI: 2.5–44.5) or 
DMFS-related event (DMFS HR: 7.8; 95% CI: 2.9–21.1). 
Based on multivariate analyses, the MammaPrint High Risk 
group showed, for DMFS, a 6.4 times higher chance for an 
event within 10 years after surgery (DMFS HR: 6.4; 95% 
CI: 2.1–19.2). Patients with tumor classified as MammaPrint 
High Risk showed an 11.1 times higher chance to develop 
a distant metastasis within 10 years after surgery (DMFI 
HR: 11.1; 95% CI: 2.3–53.0), or a 5.1 times higher chance 
to die within 10 years after surgery (OS HR: 5.1; 95% CI: 
1.5–17.2). Additionally, multivariate survival analyses were 
performed (Supplementary File 2) by including only those 
clinicopathological parameters with a significant association 
with MammaPrint outcome as shown in Table 1. These anal-
yses confirm MammaPrint as an independent factor for OS, 
DMFI, and DMFS in the patient group with LN-negative 
cases. Patient numbers were too low to report any results for 
the LN-positive subanalysis.
discussion
The results of this study validate MammaPrint as an 
independent factor for early-stage invasive lobular breast 
cancer. The significantly high HRs (up to 11 for DMFI) in 
multivariate analyses emphasize the independent value of 
MammaPrint, specifically in LN-negative invasive lobular 
breast cancers.
The study data set is comparable to ILC cohorts described 
previously.2 The current study showed a distribution of differ-
entiation grade, ER status, and HER2 status that is compa-
rable to the overall characteristics reported in a review on ILC 
by Guiu et al.2 Additionally, the percentage of MammaPrint 
Low Risk versus High Risk tumors, as well as the percentage 
of ILC patients, is comparable to that in the studies reviewed 
by Guiu et al.2 The authors of the review supported the need for 
personalized treatment by using gene expression assays, such 
as MammaPrint, for patients with lobular tumors. Because 
the patient numbers were low in the reported studies, we 
combined the results of multiple studies. In the current study, 
follow-up data of 217 ILC patients have been combined, and 
the results show a significant difference between Low Risk 
and High Risk of recurrence.
The study cohort comprises patients from five different 
clinical studies, and therefore systemic therapy decisions and 
adherence to treatment might not be fully comparable. This 
could have effect on the long-term outcome.
Demonstrating the usefulness of a test in clinical practice – 
or clinical utility – may be the most significant hurdle for 
clinical adoption of diagnostic tests. Recently, the results of 
the large Microarray In Node-negative and 1 to 3 positive 
lymph node Disease may Avoid ChemoTherapy (MIND-
ACT) trial have been reported,18 demonstrating the clinical 
utility of MammaPrint in early-stage breast cancer with Level 
1a evidence.18 This prospectively randomized study enrolled 
6693 patients, of whom 500 were classified as having ILC. 
A separate analysis of the five-year outcome data of this ILC 
group will be part of further subanalyses of the MINDACT 
clinical trial data and will provide a larger number of patients 
for whom comprehensive data are available at the level of both 
clinical risk and genomic risk. The current study was planned to 
validate the prognostic value of the MammaPrint test for ILC 
breast cancer patients, thereby supporting the clinical adop-
tion of MammaPrint prior to the comprehensive MINDACT 
analysis. The clear difference in 10-year outcome between 
MammaPrint Low Risk and High Risk patients indicates 
the utility of MammaPrint as an aid in systemic treatment 
decision for patients with early-stage ILCs, especially in the 
LN-negative group. Although IDC and ILC are recognized 
as different subgroups of the same disease with distinct clini-
cal features,3 MammaPrint has demonstrated prognostic val-
ues in the combined subgroups. The current study emphasizes 
the prognostic power of MammaPrint, specifically in primary 
invasive lobular breast cancers.
The ongoing research on breast cancer is currently focus-
ing on further stratification and substratification of IDC and 
ILC. For both breast cancer subgroups, the future lies in cre-
ating focused treatment options based on insights in patient-
specific variation19 and the combination of clinicopathological 
parameters and multiple genetic classifiers that reflect tumor 
biology for individual tumors. Clinicopathological parameters 
and established genetic classifiers, such as MammaPrint and 
BluePrint,20 can be combined with new genetic markers to 
even further identify patient subgroups with distinct relapse 
risks or benefit from specific treatment options. A specific 
example for the ILC subgroup is the identification of an 
immune-responsive subpopulation11 that can be distinguished 
using gene expression classification.
The independent value of MammaPrint in LN-negative 
early-stage invasive lobular breast cancer indicates the benefi-
cial effect of risk of recurrence determination by MammaPrint 
and subsequent adjuvant chemotherapy decision.
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chemotherapy was given to 37% of the MammaPrint Low 
Risk patients and to 75% of the MammaPrint High Risk 
patients. The goal of this study was to compare molecular 
subtyping using MammaPrint and BluePrint with standard 
immunohistochemistry and fluorescence in situ hybridization 
for predicting long-term survival in early-stage breast cancer 
patients treated at US institutions.
series 5. The cohort has been described previously by van 
de Vijver et al.14 Frozen tissue samples (n = 295) were retrospec-
tively collected for breast cancer patients treated in the NKI-
AVL (Amsterdam, the Netherlands) between 1984 and 1995, 
of which 14 were ILC. The inclusion criteria included pT1–2 
and age at diagnosis ,53 years. About one-third of the patients 
received adjuvant chemotherapy (38% of the Low Risk group 
and 37% of the High Risk group). A small portion of the patients 
received adjuvant hormonal therapy (15% of the Low Risk group 
and 13% of the High Risk group). The goal of this study was to 
evaluate and confirm the predictive power of the 70-gene signa-
ture using univariate and multivariate statistical analyses.
Flow chart sF1-2. Inclusion of cases.
notes: Inclusion of cases was based upon availability of 
Mamma Print results, survival data, and clinically important 
clinicopathological information.
abbreviations: ILC, invasive lobular carcinoma; n, number 
of patients.
table sF1-3. Frequencies showing the source of the 
study cohort.
notes: Early-stage breast cancers of the invasive lobular type 
were included from Agendia’s clinical series database (refer 
Flow chart SF1-2). The study population consisted of n = 217 
cases that were included from the five clinical series described 
herein. This table presents the numbers of cases included from 
the different clinical series.
abbreviations: HR, High Risk for MammaPrint; LN, lymph 
node; LR, Low Risk for MammaPrint; n, number of patients.
table sF1-4. Additional series information spe-
cific for the ILC patients who are part of the current study 
cohort – chemotherapy.
notes: This table presents extra information specific for the 
cases included in the current study cohort. The first column 
(Diagnosis) indicates the years of diagnosis. Additionally, infor-
mation on adjuvant chemotherapy is stratified for Mamma Print 
Low Risk, MammaPrint High Risk, and the total number of 
cases in the study cohort and the LN-negative cohort.
abbreviations: HR, High Risk for MammaPrint; LN, 
lymph node; LR, Low Risk for MammaPrint; n, number 
of patients.
table sF1-5. Additional series information specific for 
the ILC patients who are part of the current study cohort – 
hormone therapy
notes: This table presents extra information specific for 
the cases included in the current study cohort. The first 
column (Diagnosis) indicates the years of diagnosis. Addi-
tionally, information on hormone therapy is stratified for 
supplementary material
supplementary File 1. Information on clinical study series.
sF1-1. Description of series.
series 1. The cohort has been described previously by 
Michaut et al.11 Frozen tissue samples (n = 144) were ret-
rospectively collected in 2016 for patients with an invasive 
lobular carcinoma (ILC) treated in the Netherlands Cancer 
Institute–Antoni van Leeuwenhoek Hospital (NKI-AVL) 
(Amsterdam, the Netherlands) since 1980 and in the Adden-
brookes Hospital (Cambridge, UK) since 1997. From the 
NKI-AVL, consecutive tumors of patients without neoad-
juvant treatment and preferably without adjuvant hormonal 
therapy were included. From the Addenbrookes Hospital, all 
patients treated for ILC were included in the study. Overall, 
83% of the patients received adjuvant chemotherapy treat-
ment. Patients were aged between 40 years and 93 years at the 
time of diagnosis. The aim of this study was to molecularly 
characterize the ILC subgroup of breast cancers to aid tailored 
treatment and the application of specific targeted chemothera-
pies and/or immune therapies.
series 2. The cohort has been described previously by 
Bueno-de-Mesquita et al.12 Frozen breast cancer tissue sam-
ples (n = 427) were enrolled from 16 Dutch community hospi-
tals between 2004 and 2006, of which 47 were ILC tumors. The 
inclusion criteria included cT1–4, N0, and M0 invasive breast 
cancer, no neoadjuvant treatment, and age at diagnosis ,61 years. 
Further, 93% of the MammaPrint High Risk group received 
adjuvant chemotherapy, in contrast to 17% of the MammaPrint 
Low Risk group, in which 72% did not receive any adjuvant 
systemic therapy. This study aimed to perform a prospective 
feasibility study for the implementation of the 70-gene signa-
ture in a community-based setting.
series 3. The cohort has been described previously by Kok 
et al.13 In the study, three cohorts were evaluated: a data set 
with early-stage breast cancer patients who received adjuvant 
tamoxifen treatment, a data set with early-stage breast cancer 
patients who did not receive adjuvant systemic treatment, and 
a data set of metastatic breast cancer patients who received 
tamoxifen as first-line treatment. We here consider the early-
stage breast cancer patients. Frozen tissue samples (n = 272) 
were retrospectively collected for breast cancer patients with 
estrogen receptor (ER)-positive disease who were treated 
without neoadjuvant therapy in the NKI-AVL (Amsterdam, 
the Netherlands) between 1984 and 1996, of which 23 had 
ILC. This study intended to assess associations of tamoxifen 
response with the 70-gene signature and hormone receptor 
status.
series 4. Frozen tissue samples (n = 388) were retro-
spectively collected for patients treated for breast cancer 
between 1992 and 2010 at NorthShore University Health-
System (Evanston, IL, USA) and Fox Chase Cancer Center 
(Philadelphia, PA, USA), among which 41 were ILC tumors 
(manuscript in preparation). Patients were treated according 
to the relevant guidelines at the time of diagnosis. Adjuvant 
Beumer et al
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MammaPrint Low Risk, MammaPrint High Risk, and the 
total number of cases in the study cohort and the LN-nega-
tive cohort.
abbreviations: HR, High Risk for MammaPrint; LN, 
lymph node; LR, Low Risk for MammaPrint; n, number 
of patients.
supplementary File 2. Multivariate survival analyses 
including specific variables.
notes: Multivariate survival analyses were additionally per-
formed by including only those clinicopathological para meters 
that showed a significant association with MammaPrint out-
come (Table SF2-1).
table sF2-1. Multivariate survival analyses including 
significantly associated clinicopathological parameters.
notes: Shown are data from multivariate survival analyses 
of MammaPrint for the invasive lobular breast cancer study 
cohort at 10 years after surgery. HR .1 indicates that the HR 
group has a worse clinical outcome compared to the LR group. 
The reference group for each covariate in the multivariate 
model is underlined in column 2. For significant associations, 
P-values are indicated in bold. The covariate “differentiation 
grade” was entered as a continuous variable into the multivari-
ate model. aER status was assessed by TargetPrint.15
abbreviations: CI, confidence interval; ER, estrogen recep-
tor; HR, hazard ratio; HR, High Risk for Mamma Print; LN, 
lymph node; LR, Low Risk for MammaPrint.
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